CURRICULUM VITAE Gerald Louis Andriole, Jr., M.D. Address ...
CURRICULUM VITAE Gerald Louis Andriole, Jr., M.D. Address ... CURRICULUM VITAE Gerald Louis Andriole, Jr., M.D. Address ...
Administered Orally Once Daily for Four Years to Reduce the Risk of Biopsy- Detectable Prostate Cancer CURRENT Funding Agency: Period: Grant Title: Aeterna Zentaris 2007-present Study Z033: Cetrorelix Pamoate Intermittent IM Dosage Regimens in Patients with Symptomatic BPH: A 1 Year Placebo-Controlled Efficacy Study and Long-Term Safety Assessment 10
BIBLIOGRAPHY: I. ABSTRACTS 1. Andriole, G.L., Lack E., Bauer, S.B., Colodny, A.H., Retik, A.B.: Transitional Cell Carcinoma f the Bladder in Children. 77th Annual Meeting, American Urological Association 1982. 2. Andriole, G.L. and Yalla, S.V.: Non-neurogenic Bladder Neck Obstruction in Adult Males -- Fact or Fiction. 78th Annual Meeting, American Urological Association, 1983. 3. Andriole, G.L. and Mahoney, E.M.: Benign Intratesticular Cysts. 78th Annual Meeting, American Urological Association, 1983. 4. Andriole, G.L. and Yalla, S.V.: Alterations in Urinary Continence Mechanisms Following Radical Prostatectomy. 78th Annual Meeting, American Urological Association, 1983. 5. Linehan, W.M., Kish, M.L., Santora, A.C., Andriole, G.L., Gray, T.K.: DU94, Human Prostate Carcinoma causes hypercalcemia in the Athymic Nude Mouse/ 6th Annual Meeting, American Society for Bone and Mineral Research, Hartford, Connecticut, 1984. 6. Andriole, G.L., Loriaux, L.D., Rittmaster, R.S., Kish, M.L., Linehan, W.M.: Treatment of androgen responsive human genitourinary tumors with 4MA, a potent inhibitor of 5-alpha reductase. 80th Annual Meeting, American Urological Association. J. Urol. 133:123A, 1985. 7. Andriole, G.L., Frank, M.M., Mostofi, F.K., Linehan, W.M.: Danazol-induced cystitis in patients with hereditary angioneurotic edema. 80th Annual Meeting, American Urological Association. J. Urol. 133:169A, 1985. 8. Andriole, G.L., Magrath, I.T., Linehan, W.M.: The uroprotective role of 2-mercaptoethane (MESNA) in patients receiving high dose cyclophosphamide or isophosphamide chemotherapy: Experience with 25 patients. 80th Annual Meeting, American Urological Association. J. Urol. 133:169A, 1985. 9. Andriole, G.L., Macher, A., Masur, H., Fauci, A., Lane, H.C. and Linehan, W.M.: Genitourinary manifestations in patients with acquired immunodeficiency syndrome. 80th Annual Meeting, American Urological Association. J. Urol. 133:192A, 1985. 10. Kelly, D.R., Kavoussi, L.J., Andriole, G.L.: Bladder cancer progression in patients treated with prolonged intravesical BCG therapy. 81st Annual Meeting, American Urological Association. J. Urol. 135:285A, 1986. 11. Andriole, G.L.: MBT-2 is Sensitive to Lysis by Lymphokine Activated Killer Cells Derived from C 3 He Mice. 82nd Annual Meeting, American Urological Association. J. Urol. 137:146A, 1987. 12. Andriole, G.L., Rudloff, M.A., and Becich, M.: Initial Experience with Needle Aspiration Cytology in the Diagnosis of Prostate Cancer. 82nd Annual Meeting, -American Urological Association. J. Urol. 137:192A, 1987. 13. Andriole, G.L., and Ratliff, T.L.: The Effect of Interleukin-2 and Lymphokine Activated Killer Cells on the Development of Murine Bladder Tumors. 73rd Clinical Congress of the American College of Surgeons, 1987. 11
- Page 1 and 2: CURRICULUM VITAE Gerald Louis Andri
- Page 3 and 4: Chairman, Steering Committee, REDUC
- Page 5 and 6: Period: 2002-2009 Grant Title: Comp
- Page 7 and 8: Grant Title: A Double-Blind, Random
- Page 9: implant) in Community-Based Patient
- Page 13 and 14: 27. Andriole, G.L., Coplen, D.E., a
- Page 15 and 16: 52. Andriole, G.L., Rao, G.S., Kawa
- Page 17 and 18: 76. Yan, Y., Andriole, G.L., Diaz,
- Page 19 and 20: 99. Albala, D.M., Andriole, G.L., D
- Page 21 and 22: 123. Grubb RL III, Black A, Church
- Page 23 and 24: 28. Clayman, R.V., McClennan, B.W.,
- Page 25 and 26: 60. Keetch, D.W., Andriole, G.L., C
- Page 27 and 28: 90. Monk, T.G., Goodnough, L.T., Br
- Page 29 and 30: Thermotherapy (P-TUMT) for the Trea
- Page 31 and 32: 144. Andriole, G.L., Bostwick, D.,
- Page 33 and 34: 170. Marks, L.S., Roehrborn, C.G. a
- Page 35 and 36: D.S., Chanock, S.J., Thun, M.J. and
- Page 37 and 38: 14. Andriole, G.L.: Tumor markers i
Administered Orally Once Daily for Four Years to Reduce the Risk of Biopsy-<br />
Detectable Prostate Cancer<br />
CURRENT<br />
Funding Agency:<br />
Period:<br />
Grant Title:<br />
Aeterna Zentaris<br />
2007-present<br />
Study Z033: Cetrorelix Pamoate Intermittent IM Dosage<br />
Regimens in Patients with Symptomatic BPH: A 1 Year Placebo-Controlled<br />
Efficacy Study and Long-Term Safety Assessment<br />
10
Change language